Arcutis Biotherapeutics Inc   (ARQT)
Other Ticker:  
Price: $11.7700 $1.49 14.494%
Day's High: $11.91 Week Perf: 21.47 %
Day's Low: $ 10.00 30 Day Perf: 100.51 %
Volume (M): 6,826 52 Wk High: $ 15.47
Volume (M$): $ 80,343 52 Wk Avg: $7.54
Open: $10.19 52 Wk Low: $1.76

 Market Capitalization (Millions $) 816
 Shares Outstanding (Millions) 69
 Employees 68
 Revenues (TTM) (Millions $) 60
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) 0

Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc is a pharmaceutical company focused on developing and commercializing innovative immunology and dermatology therapies to treat immune-mediated dermatological diseases, including psoriasis, atopic dermatitis, and seborrheic dermatitis. The company was founded in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics' pipeline includes several dermatology drug candidates, including ARQ-252, a topical treatment for chronic hand eczema that is currently in Phase 3 clinical trials; ARQ-154, a topical cream for the treatment of seborrheic dermatitis that has completed Phase 2 clinical trials and is expected to enter Phase 3 trials; and ARQ-171, a topical foam formulation currently in Phase 2 clinical trials for the treatment of atopic dermatitis.

The company's lead product candidate is ARQ-151, a topical cream for the treatment of plaque psoriasis. ARQ-151 received FDA approval in December 2020 and became available on the market in February 202

Beyond its dermatology pipeline, Arcutis Biotherapeutics is developing ARQ-531, a small-molecule inhibitor for the treatment of B-cell malignancies and other blood cancers. ARQ-531 is currently in Phase 1 clinical trials.

Arcutis Biotherapeutics has partnered with several leading pharmaceutical companies, including LEO Pharma and SQ Innovation, to advance its pipeline and bolster its research and development efforts. The company's goal is to provide innovative and effective treatments for patients suffering from dermatological diseases, and to become a leading player in the dermatology and immunology markets.

   Company Address: 3027 Townsgate Road Westlake Village 91361 CA
   Company Phone Number: 418-5006   Stock Exchange / Ticker: NASDAQ ARQT


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Financing Agreement

Arcutis Biotherapeutics: Paving the Path to Success Amidst Market Challenges

Published Wed, Feb 28 2024 9:10 PM UTC

In a move aimed at bolstering its financial position and fueling its ambitious growth plans, Arcutis Biotherapeutics Inc has announced a public offering of $150.0 million worth of common stock. While this development highlights the company's commitment to expanding its operations, it is essential to analyze the facts surrounding Arcutis and assess the impact of rec...

Product Service News

Arcutis and Sato Forge Path for Revolutionary Dermatological Breakthroughs in Japan with Topical Roflumilast Collaboration

Published Wed, Feb 28 2024 9:00 PM UTC

Arcutis and Sato: Revolutionizing Dermatological Solutions through Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanIn a groundbreaking move, Arcutis, a leading dermatology-focused biopharmaceutical company, and Sato, a renowned Japanese pharmaceutical company, have joined forces in a strategic collaboration and licensing agreement for the deve...

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc Achieves Record Revenue Growth of 356.805% in Q4 20232.

Arcutis Biotherapeutics Inc, a leading innovator in dermatology therapeutics, recently announced its financial results for the fourth quarter of 2023, showing significant improvements in various key metrics. The company's success can be attributed to its ongoing efforts to develop effective treatments for dermatological conditions, as demonstrated by the positive results from the pivotal Phase 3 STRATUM trial.
Financial Performance:
In the fourth quarter of 2023, Arcutis Biotherapeutics Inc saw a decrease in its loss per share, with $0.68 per share compared to $1.06 in the previous year. Furthermore, the company reported an increase in earnings per share from the previous reporting season, with $0.73 per share in contrast to the negative $0.73 per share previously.

Clinical Study

Promising Results from Phase 3 Trial of ZORYVE (roflumilast) Foam, 0.3% in Seborrheic Dermatitis

Published Mon, Jan 29 2024 1:00 PM UTC

Arcutis Biotherapeutics Inc, a leading innovator in dermatology therapeutics, has recently announced the publication of positive results from the pivotal Phase 3 STRATUM trial evaluating the efficacy of ZORYVE (roflumilast) foam, 0.3% for the treatment of seborrheic dermatitis. Published in the Journal of the American Academy of Dermatology (JAAD), these findings highlight t...

Clinical Study

ZORYVE (Roflumilast) Topical Foam: A Promising Treatment for Seborrheic Dermatitis

Published Sun, Jan 14 2024 9:00 AM UTC

Seborrheic dermatitis is a common chronic skin condition characterized by red, itchy, and flaky skin. Topical steroids have long been the primary treatment option, but a significant proportion of patients experience inadequate responses. In a recent subgroup analysis of the STRATUM study, Arcutis announced the successful clearance of seborrheic dermatitis using ZORYVE (Roflu...


Arcutis Biotherapeutics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Arcutis Biotherapeutics Inc does not provide revenue guidance.

Earnings Outlook
Arcutis Biotherapeutics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com